NeurAxisNASDAQ: NRXS

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

09 August 2023

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$14.48 M
-56%vs. 3y high
21%vs. sector
-vs. 3y high
-vs. sector
-50%vs. 3y high
8%vs. sector
-60%vs. 3y high
66%vs. sector

Price

regular market | 40 min ago
$2.69+$0.06(+2.28%)

Dividend

No data over the past 3 years
$611.50 K-$2.92 M

Analysts recommendations

Institutional Ownership

NRXS Latest News

Zacks Initiates Coverage of NeurAxis With Neutral Recommendation
zacks.com25 September 2024 Sentiment: POSITIVE

Discover why Zacks rates NeurAxis as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore NRXS' promising growth prospects and financial health amid market challenges.

NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
globenewswire.com19 September 2024 Sentiment: POSITIVE

CARMEL, Ind., Sept. 19, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, taking place virtually on Tuesday, October 1, 2024.

NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024
globenewswire.com13 August 2024 Sentiment: POSITIVE

CARMEL, Ind., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), for Blue Cross Blue Shield (BCBS) of Vermont Medical Members, effective 10/1/2024. This medical policy will bring our national total coverage for PENFS to roughly 23 million, with more decisions from major payers still pending.

NeurAxis, Inc. (NRXS) Q2 2024 Earnings Call Transcript
seekingalpha.com11 August 2024 Sentiment: NEUTRAL

NeurAxis, Inc. (NYSE:NRXS ) Q2 2024 Earnings Conference Call August 9, 2024 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Chief Financial Officer Conference Call Participants Mark Foster - Kirr Marbach & Co Operator Good day and thank you for standing by. Welcome to NeurAxis Reports Second Quarter 2024 Financial Results.

NeurAxis Reports Second Quarter 2024 Financial Results
globenewswire.com09 August 2024 Sentiment: POSITIVE

Carmel, Ind., Aug. 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the second quarter period ended June 30, 2024.

NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure
globenewswire.com07 June 2024 Sentiment: POSITIVE

CARMEL, Ind., June 07, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced a submission to the FDA for expansion of its IB-Stim label. The new submission is significant as it would allow access to a larger patient population beyond 11-18 years of age and allow for marketing of 4 devices per prescription.

NeurAxis, Inc. (NRXS) Q1 2024 Earnings Call Transcript
seekingalpha.com22 May 2024 Sentiment: POSITIVE

NeurAxis, Inc. (NYSE:NRXS ) Q1 2024 Earnings Conference Call May 22, 2024 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Chief Financial Officer Operator Good day, and thank you for standing by. Welcome to NeurAxis Reports First Quarter 2024 Financial Results.

NeurAxis Reports First Quarter 2024 Financial Results
globenewswire.com22 May 2024 Sentiment: POSITIVE

CARMEL, Ind., May 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2024 for the period ended March 31, 2024.

Medtech company NeurAxis upsizes IPO and lowers price to $6 a share vs. $8 previously
Market Watch21 July 2023 Sentiment: NEGATIVE

NeurAxis, a medical technology company with an FDA-approved therapy to treat abdominal pain associated with IBS in adolescents aged 11 to 18 years old, tweaked the terms of its initial public offering on Friday. In a filing with the Securities and Exchange Commission, the company said it now plans to offer 1.7 million shares priced at $6 each, while selling shareholders will offer 2.8 million shares.

What type of business is NeurAxis?

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

What sector is NeurAxis in?

NeurAxis is in the Healthcare sector

What industry is NeurAxis in?

NeurAxis is in the Biotechnology industry

What country is NeurAxis from?

NeurAxis is headquartered in United States

When did NeurAxis go public?

NeurAxis initial public offering (IPO) was on 09 August 2023

What is NeurAxis website?

https://neuraxis.com

Is NeurAxis in the S&P 500?

No, NeurAxis is not included in the S&P 500 index

Is NeurAxis in the NASDAQ 100?

No, NeurAxis is not included in the NASDAQ 100 index

Is NeurAxis in the Dow Jones?

No, NeurAxis is not included in the Dow Jones index

When was NeurAxis the previous earnings report?

No data

When does NeurAxis earnings report?

Next earnings report date is not announced yet